Voya Investment Management LLC Sells 9,125 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Voya Investment Management LLC decreased its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 12.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,196 shares of the biopharmaceutical company’s stock after selling 9,125 shares during the period. Voya Investment Management LLC owned 0.07% of Ultragenyx Pharmaceutical worth $2,288,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 323 shares during the period. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical in the first quarter worth about $57,000. Headlands Technologies LLC bought a new position in shares of Ultragenyx Pharmaceutical in the first quarter worth about $59,000. Covestor Ltd boosted its stake in shares of Ultragenyx Pharmaceutical by 86.8% in the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 795 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter worth about $82,000. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $28.13 on Monday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $25.81 and a 1 year high of $59.50. The business has a 50 day simple moving average of $28.97 and a two-hundred day simple moving average of $33.92. The firm has a market capitalization of $2.71 billion, a PE ratio of -5.09 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The business had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. During the same quarter in the previous year, the business earned ($1.52) earnings per share. The company’s revenue for the quarter was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company’s stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on RARE shares. Wells Fargo & Company dropped their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th. Guggenheim restated a “buy” rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Morgan Stanley cut their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, July 14th. William Blair started coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price objective for the company. Finally, Wedbush cut their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research report on Monday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.